Floxicam

Quick links to important sections

Floxicam

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Floxicam

Property Description
Active ingredient Piroxicam
Forms Capsules, tablets, injectable solution, suppositories, gel, and cream
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Relieving pain and reducing inflammation
Origin Synthetic compound

Floxicam: Definition, Classification, and Composition

Floxicam is a synthetic pharmaceutical preparation defined by its sole active ingredient, Piroxicam. It is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), a class of medication used to address pain and reduce inflammation. As an oxicam derivative, Piroxicam is structurally grouped with enolic acid compounds, distinguishing it from other NSAID types and contributing to its duration of effect. This medicine is supplied as a single-active ingredient product and is generally dispensed as a prescription medicine (Rx).


What are the Available Forms and General Therapeutic Purpose?

Floxicam is provided in multiple dosage forms, allowing for delivery via both systemic administration (capsules, tablets, injectable solutions, and suppositories) and topical administration (gels and creams). This broad presentation profile, offering both localized and internal options, provides flexibility in treatment selection. The general therapeutic purpose of Floxicam is to reduce swelling and provide relief from pain by inhibiting the action of cyclooxygenase (COX) enzymes, a mechanism associated with the decreased production of inflammatory messengers. This action provides both an analgesic effect and an anti-inflammatory effect, making it useful for managing discomfort associated with conditions such as chronic musculoskeletal ailments and acute instances of joint inflammation.

Regulatory References

  1. Piroxicam - LiverTox - NIH

What side effects are possible with Floxicam?

Possible Side Effects and Safety Information

Floxicam (Piroxicam) safety information is governed by official government regulatory documents, outlining adverse reactions categorized by frequency and physiological system.

Serious Systemic Risks and Warnings

The most serious safety concerns documented in regulatory labels relate to major organ systems. The medicine is associated with an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with the duration of use. Furthermore, there is a risk of serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time during treatment, often without warning symptoms. Rare but serious skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have also been reported, with the highest risk noted during the initial weeks of therapy.

Common Adverse Reactions and Organ Systems

Adverse reactions frequently observed in clinical use and classified as common in official documents primarily involve the Gastrointestinal System and Nervous System. These include nausea, abdominal pain, diarrhea, constipation, headache, and dizziness. Edema (fluid retention) is also commonly reported. The reactions are grouped by System-Organ-Class, including Gastrointestinal, Cardiovascular, Renal, Hepatic, and Nervous systems.

Population-Specific Safety Notes

The official label includes specific safety constraints for certain populations. Older adults have an increased risk of serious adverse reactions, particularly fatal gastrointestinal bleeding and perforation. Use is contraindicated in the setting of peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery and is also to be avoided in late pregnancy (from about 30 weeks gestation) due to fetal risk. The medicine is also restricted for individuals with active peptic ulceration or severe heart failure.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory guidance documents define the Floxicam overdose profile by detailing a range of documented clinical manifestations and required emergency actions. Overdose presentations commonly involve the gastrointestinal system, the central nervous system, and the cardiovascular system.

Documented manifestations include nausea, vomiting, and stomach pain, alongside potentially serious signs of bleeding, such as black or bloody stools. Central nervous system effects may present as severe headache, confusion, agitation, or, in severe cases, convulsions and decreased consciousness leading to coma. Cardiovascular signs often involve low blood pressure.

Mandatory Emergency Action

Immediate emergency medical attention is mandatory upon suspicion of overdose. Regulatory statements mandate contacting emergency services or a Poison Help line immediately, even if symptoms are not yet apparent. Urgent care is necessary if documented severe outcomes are present, including loss of consciousness, seizures, acute renal failure (little to no urine production), or signs of gastrointestinal hemorrhage. Individuals with pre-existing kidney or liver disease are noted to be at an increased risk for serious outcomes in this context.

Overdose Management

Management is officially described as symptomatic and supportive, as no specific antidote is known for Floxicam overdose. This includes, if appropriate, gastric decontamination with activated charcoal. Monitoring requirements involve continuous assessment of vital signs, including heart function (ECG), along with blood and urine tests. Specialized procedures may be required depending on the documented severity and organ involvement.

Therapeutic Uses of Floxicam

What Floxicam Treats: Main Uses and Benefits

Floxicam is commonly used in clinical contexts where additional symptomatic support is needed in long-term conditions, such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is also relevant for managing symptoms associated with acute gouty arthritis, acute musculoskeletal manifestations, and primary dysmenorrhea. The medication may help address the overall symptom burden related to persistent pain and stiffness, contributing to supporting day-to-day comfort during symptomatic periods.

“The medication is applied across domains where symptoms cluster into patterns requiring supportive management.”

It is applied during phases when symptoms become more noticeable, offering supportive therapeutic benefit that may assist with managing functional strain and symptoms that create noticeable physiological strain.

Quick Fact: Relief for Inflammatory Discomfort

Floxicam is relevant for easing symptoms related to inflammatory or irritative states, specifically targeting joint swelling, tenderness, and morning stiffness that interfere with daily functioning.

Regulatory References

  1. ankylosing spondylitis

Eligibility and Restrictions for Use

This section outlines official eligibility and exclusion criteria for Floxicam, based on regulatory labeling for related Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) such as Meloxicam and Piroxicam.

Eligibility scope

Category Official Regulatory Status
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or any component; those with a history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs; and patients in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Populations for whom use is not recommended Nursing Mothers; patients with severe heart failure or advanced renal disease (unless the benefit clearly outweighs the risk); and patients with active gastrointestinal ulcerations.

Condition-specific eligibility rules

  • Pregnancy: Use must be avoided in women who are at 30 weeks gestation and later due to documented risk of fetal harm. Use is restricted between about 20 to 30 weeks of pregnancy.
  • Organ Function: Use requires caution and monitoring in patients with pre-existing conditions such as hypertension, heart failure, or hepatic impairment.
  • Age: Use is established for certain indications in adults and some pediatric patients ge 2 years of age, but caution is necessary for the elderly due to increased risks.

Official regulatory documents define absolute contraindications for patients with drug hypersensitivity and those post-CABG, thus excluding them from use. The profile dictates restricted use for individuals with pre-existing severe cardiac or renal disease and women in late pregnancy, defining a high-risk group that generally must not use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formal Regulatory Prohibitions and Restrictions

The official regulatory profile strictly states that piroxicam is contraindicated for the management of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other non-aspirin systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is documented to be avoided due to the increased risk of gastrointestinal adverse events. Use with analgesic doses of aspirin is also generally not recommended by regulatory authorities.

Pharmacodynamic and Exposure Interactions

The profile details interactions that reinforce physiological effects. Co-administration with anticoagulants (such as warfarin), antiplatelet agents, and SSRIs officially increases the risk of bleeding. Piroxicam also reduces the natriuretic effect of diuretics and can diminish the antihypertensive effect of ACE Inhibitors, ARBs, and Beta-Blockers.

Furthermore, piroxicam can increase the systemic exposure and reduce the renal clearance of co-administered medicines, including lithium and digoxin. Consumption of alcohol is also documented to increase the risk of serious gastrointestinal bleeding.

Metabolic and Population-Specific Cautions

Piroxicam’s primary metabolism is via the CYP2C9 enzyme. Individuals documented as CYP2C9 poor metabolizers exhibit higher systemic drug exposure due to reduced clearance. In specific populations, such as the elderly or those with renal impairment, co-administration with ACE Inhibitors or ARBs may result in a documented deterioration of renal function.

Mechanism of Action

Floxicam (Piroxicam) acts through the reversible, non-selective inhibition of the COX-1 and COX-2 enzymes. This interaction blocks the fundamental biochemical step of converting arachidonic acid into key inflammatory mediators. This engagement of the enzyme synthesis pathway is the action required to decrease the synthesis of inflammatory and nociceptive signaling molecules at their source.

The consequence of COX inhibition is the immediate and widespread suppression of prostaglandin synthesis. Reduced prostaglandin levels directly affect the physiological processes of inflammation, decreasing localized vasodilation and limiting the sensitization of peripheral nociceptors (pain receptors). This pathway modulation also influences central nervous system activity, modulating the central set point for body temperature and contributing to the modulation of nociception and thermoregulation.

The drug’s non-selective mechanism, which involves inhibiting both COX isoforms, places a constraint on its action by also blocking homeostatic functions dependent on COX-1. This includes the reduction of protective prostaglandins necessary for gastric mucosal integrity and the concurrent inhibition of thromboxane synthesis in platelets, which functionally modulates the process of aggregation.

Dosage and Administration Information

How to Use Floxicam

Floxicam (Piroxicam) usage is defined by its administration routes, dosing patterns, and duration limits. The medication is indicated for oral, intramuscular (IM), and rectal administration, with forms including capsules, tablets, injectable solutions, and suppositories.


Dosing Principles and Administration

Administration is differentiated based on the condition being addressed, adhering to the principle of using the lowest effective dosage for the shortest duration necessary.

Condition Type Initial Dosing Regimen Maximum Daily Limit (Chronic)
Chronic (OA, RA, AS) 20 mg once daily or 10 mg twice daily 20 mg
Acute (Gout, MSK) 40 mg daily for the initial 1–2 days Higher doses (40 mg) are limited to short-term acute initiation only

For chronic conditions, the full anti-inflammatory response may require continuous use for up to two weeks, with plasma steady-state levels typically achieved within 7 to 12 days. Treatment for acute flares, such as acute gouty arthritis, is typically restricted to a short course of four to six days.

Oral dosage forms, including the capsule and tablet, should be taken with or immediately following food and a full glass of water. This intake protocol is utilized to support gastrointestinal tolerability. Intramuscular injection is reserved for initial treatment phases or when the oral route is not feasible, with conversion to oral forms transitioned as soon as practical.

Recent Clinical Evidence

Floxicam: Recent Clinical Evidence

Evidence for Moderate-to-Severe Plaque Psoriasis

Research has evaluated the combined data to examine Floxicam’s potential application for moderate-to-severe plaque psoriasis.

  • Outcomes related to clear or nearly clear skin were assessed using the Psoriasis Area and Severity Index (PASI 90 and PASI 100).
  • Clinical trials have explored Floxicam’s effects on symptoms such as redness, scaling, and itching, including the onset and duration of response.
  • In clinical trials, a reduction in symptom severity was reported by participants within the first 12 weeks of assessment.

Research on Activity Pathway

Research has examined the role of inflammatory cytokines in Floxicam's activity; studies have investigated this pathway's association with skin healing.

  • The investigated pathway involves Floxicam's activity against specific proteins in the inflammatory process.
  • Measures related to inflammation were examined for their potential association with overall quality of life measures.
  • Trials have collected data on skin clearance outcomes (PASI 100) and response durability in participants receiving Floxicam.

Assessment of Long-Term Use

The agent's characteristics, including potential adverse effects, were assessed in trials involving long-term use in adult participants.

  • Commonly reported adverse events in studies included injection-site reactions and upper respiratory tract infections.
  • Serious adverse events, such as major infections or malignancy, were recorded and tracked in the trial population.
  • Studies examined the long-term outcomes and maintenance of response over periods up to 18 months.
  • Ongoing research is exploring Floxicam's activity in other autoimmune conditions.

Frequently Asked Questions (FAQ)

Common questions about Floxicam (FAQ)

Q: How long does it typically take to start feeling the effects of Floxicam?

While the full anti-inflammatory effect of Floxicam may require continuous use for up to two weeks to reach steady-state concentration, the initial pain-relieving (analgesic) effect is typically noted relatively quickly. Official product information describes the required dosing frequency to maintain consistent levels of the medicine over time.

Q: If I miss a dose of Floxicam, what should I generally do?

Official patient instructions generally advise that if a dose is missed, the protocol is to take it as soon as it is remembered, unless it is close to the time for the next scheduled dose. If the next dose is due soon, the protocol is generally to skip the missed dose and resume the regular schedule. This practice helps avoid taking too much medicine within a short period.

Q: Can older adults typically use Floxicam safely, or are there special considerations?

Regulatory documents recommend that caution is used when prescribing Floxicam for older adults. This is due to an increased risk of serious side effects, particularly concerning gastrointestinal bleeding. Healthcare professionals may consider a reduced starting dose based on individual patient circumstances.

Q: Is Floxicam related to ibuprofen or naproxen in its class of drugs?

Yes, Floxicam (Piroxicam) is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This is the same broad class of medication as common drugs like ibuprofen and naproxen, meaning they share a similar mechanism of action for pain and inflammation relief.

Q: Does the time of day I take Floxicam affect how well it works?

Official dosing instructions specify the frequency, such as once or twice daily, that is necessary to ensure a steady level of the medicine is maintained in the body. Maintaining a consistent dosing schedule, as outlined in the official instructions, supports the drug’s intended effectiveness by ensuring a steady level in the body.

Q: Why is Floxicam sometimes prescribed for pain that is not related to inflammation?

The mechanism of action for Floxicam includes two components: an analgesic effect, which provides relief from pain, and an anti-inflammatory effect, which reduces swelling. Because of its dual action, the medicine may be used to manage pain symptoms even when inflammation is not the primary cause of discomfort.

Q: What are some signs that a side effect from Floxicam might be serious?

Serious side effects described in official labeling may be accompanied by signs such as severe abdominal pain, unexplained weight gain, yellowing of the skin or eyes (jaundice), or new onset of shortness of breath. If a serious reaction is suspected, official sources advise that immediate medical help should be sought.

Q: Is there a risk of dependency or addiction with Floxicam?

Floxicam (Piroxicam) is not listed as a controlled substance by regulatory bodies like the NIH or FDA. This classification indicates that the medicine does not carry the risk of dependency or addiction associated with scheduled medications.

Q: How is Floxicam generally eliminated from the body?

Regulatory text on pharmacokinetics states that Floxicam is extensively broken down (metabolized) in the liver, primarily through the CYP2C9 enzyme. The drug is then eliminated from the body predominantly through the urine and feces.

Q: What should be done if an accidental overdose of Floxicam is suspected?

Official instructions advise that immediate contact should be made with a poison control center or emergency medical attention sought if an accidental overdose of Floxicam is suspected.

Q: Can a person stop taking Floxicam suddenly, or is tapering usually advised?

The prescribing information typically does not specify a tapering protocol for Floxicam. Discontinuation is generally guided by a healthcare professional based on the resolution of acute symptoms or a periodic reassessment of the ongoing treatment.

Q: What research evidence exists regarding Floxicam's use in children?

Regulatory documents indicate that use of Floxicam is established for certain indications, such as juvenile arthritis, in children aged two years and older. This confirms that supporting research and data have been reviewed by regulatory authorities.

Q: What is the difference between brand-name Floxicam and the generic version?

Generic versions of Floxicam contain the exact same active ingredient (Piroxicam) as the brand-name version. Regulatory agencies require both generic and brand-name drugs to meet the same strict standards for quality, effectiveness, and strength.

Q: Is the onset of action different between the tablet and capsule forms of Floxicam?

Pharmacokinetic data included in official documents generally confirms that the bioavailability and absorption rate for the tablet and capsule oral solid dosage forms of Floxicam are comparable.

Q: Are there common signs of an interaction when taking Floxicam with another drug?

The product label highlights potential drug interactions that increase the risk of bleeding, such as when Floxicam is taken with blood thinners. Observable signs of this type of interaction could include easy bruising, blood in the urine or stool, or bleeding that takes an unusually long time to stop after a minor cut.

Q: What is the maximum duration of time Floxicam is generally recommended to be used?

Regulatory text advises using the lowest effective dosage for the shortest possible duration. Specific limits are defined for acute conditions, such as a short course of four to six days for acute gout. The overall duration of use is determined by the healthcare provider based on the treated condition.

Q: Can Floxicam cause sensitivity to the sun?

Yes, regulatory safety information for Floxicam lists photosensitivity, which is an increased sensitivity to the sun, as a reported adverse reaction.

Q: What is the general half-life of Floxicam?

Pharmacokinetic data in regulatory documentation states that Floxicam has a notably prolonged half-life, which is approximately 50 hours.

Q: What are the official recommendations for discontinuing Floxicam use?

Official guidance indicates that the need for discontinuation is typically guided by the resolution of acute symptoms or is based on a healthcare professional's periodic reassessment of the benefits and risks of chronic therapy.

Q: Does Floxicam have a defined role in managing chronic pain?

Yes, Floxicam is specifically indicated in regulatory documents for the long-term management of chronic inflammatory conditions. These include both osteoarthritis (OA) and rheumatoid arthritis (RA).

Q: What is the difference between a side effect and an allergic reaction to Floxicam?

Official safety information defines a side effect as an unintended effect that occurs when the medicine is taken at normal doses, such as dizziness or stomach discomfort. An allergic reaction, however, is a severe, immune-mediated response that is listed as a specific contraindication or serious warning in the product label due to the potential for life-threatening symptoms.

How should Floxicam be stored and disposed of?

How to Store and Dispose of Floxicam (Piroxicam)

Official regulatory guidelines define specific conditions for storing and disposing of Floxicam (Piroxicam) to maintain its integrity and ensure safety.

Storage Requirements

Floxicam must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). The medication must be kept away from excessive heat, moisture, and light, and should remain in its original container with the cap tightly closed. It is a mandatory requirement that Floxicam be stored out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Floxicam should be managed according to a Regulatory Disposal Protocol. This requires using a drug take-back program or securely disposing of the product in household trash, mixed with an unappealing substance and sealed in a container. The medication must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Floxicam found in:

A-Z Index: